MGMT and central nervous system cancer: Recruitment into clinical trials is largely based on a histological diagnosis of glioma, with or without specific genetic markers such as isocitrate dehydrogenase (IDH) and O6-methylguanine-DNA methyltransferase (MGMT) gene methylation.